Clinical trials: Immunity
Multiple Organ Dysfunction Syndrome
Pediatric Immune Response to Multi-Organ Dysfunction
Multiple organ dysfunction (MOD) is defined by the association of at least two failures of vital organs, with various etiologies (septic shock, polytrauma, acute respiratory distress syndrome, etc.).
- Trial name
- PedIMOD (NCT04438460)
- Testing
- Blood test
- Where
- 2 sites in France
- Volunteers
- 186 people
- Sponsor
- Hospices Civils de Lyon
Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA)
Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives
The investigators are conducting a research study to understand how cells responsible for fighting infection (immune cells) are affected by hormonal contraceptive use.
- Conditions
- Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA), Initiation of Mirena (LNG-IUD)
- Trial name
- NCT01750476
- Testing
- Mirena, Oral contraception, Depo-Provera
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Thomas Cherpes, DVM, MD
Immunization; Infection
Immunisation History Survey - a Study to Measure Levels of Immunity to Routine Immunisations
To collect the immunisation history of participants enrolled in a previous vaccine study (REC 09/H0604/107) in order to assess the influence of genetic variation on the level of immunity to routine immunisations.
- Trial name
- NCT03145324
- Testing
- Collection of vaccine histories
- Where
- United Kingdom
- Volunteers
- 166 people
- Sponsor
- University of Oxford
Monkeypox
A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
This study is a Phase 2 open-label, non-placebo controlled, multi-site clinical trial that will evaluate the standard SC regimen in adolescents ages 12 through 17 years, inclusive, and compared to the standard subcutaneous…
- Trial name
- NCT05740982
- Testing
- JYNNEOS
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Poliomyelitis
Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine
As poliovirus eradication progresses rapidly, strategies to discontinue oral poliovirus vaccination need to be established. One strategy would be to use inactivated poliovirus vaccine (IPV) transitionally, and this has already…
- Trial name
- NCT00137696
- Testing
- Vaccination with inactivated polio vaccine, Collection of serum
- Where
- Puerto Rico
- Volunteers
- 473 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Inborn Errors of Immunity
Immunodysregulation As an Expression of Underlying Inborn Errors of Immunity: Implementation of Diagnostics and Management of Pediatric and Adult Patients with Immune System Disorders
This is an observational, retro-prospective, moncentric study focused on Inborn Errors of Immunity, an heterogeneous group of inherited diseases due to defects in the differentiation and/or function of the immune system.
- Trial name
- NCT06773546
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Prevention of Meningococcal Disease
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
The purpose of this study is to evaluate the safety, immunogenicity and induction of immune memory after two or three doses of Novartis (Formerly Chiron) Meningococcal ACWY Conjugate Vaccine administered to healthy infants.
- Trial name
- NCT00262002
- Testing
- MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation), MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation), MenACWY PS (MenACWY-CRM, polysaccharide vaccine)
- Where
- 3 sites in Canada, United Kingdom
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Vaccination; Infection, Maternal-Fetal Relations
Maternal Determinants of Infant Immunity to Pertussis
The overall objective of the project is to identify the determinants of antibody-mediated immunity in infants born to mothers immunized during pregnancy.
- Conditions
- Vaccination; Infection, Maternal-Fetal Relations, Pertussis, Immunoglobulins
- Trial name
- MADI-02 (NCT05856396)
- Testing
- Triaxis® (Pertussis-containing vaccine), Vaxelis® (Pertussis-containing vaccine)
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Polio
Evaluation of Buffer on Immune Response to Oral Polio Vaccine (OPV) in Bangladesh
Hypothesis: The immunogenicity of oral polio vaccine (OPV) will be enhanced in Bangladeshi infants who receive bicarbonate buffer at the time of polio immunization.
- Trial name
- NCT01579825
- Testing
- Buffer
- Where
- Bangladesh
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Diphtheria, Polio
Safety and Immune Response of Different Pediatric Combination Vaccines.
The overall aim of the study is to corroborate that a schedule consisting of 3 doses of Pentacel™ and a 4th dose of DAPTACEL® and ActHIB® or 4 doses of Pentacel™ or 4 doses of Quadracel and ActHIB® is as safe and immunogenic as a…
- Conditions
- Diphtheria, Polio, Pertussis
- Trial name
- NCT00255047
- Testing
- DAPTACEL®. (DTaP), IPOL®., and ActHIB®., Pentacel®: DTaP-IPV/Hib combined, DTaP-IPV and ActHIB®
- Where
- 36 sites in United States
- Volunteers
- 2,167 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Primary Immune Deficiency Disorders (PIDD)
Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
The purpose of this study is to determine if NABI-IGIV (10%) [Immune Globulin Intravenous (Human), 10%] is safe and effective in preventing serious bacterial infections (SBIs) in the treatment of patients with primary immune…
- Trial name
- NCT00538915
- Testing
- Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
- Where
- 17 sites in United States
- Volunteers
- 63 people
- Sponsor
- ADMA Biologics, Inc.
HIV Infections
Immune and Viral Outcomes of HIV-1 Therapy Interruption
The purpose of this study is to determine if stopping anti-HIV drugs for a period of time is safe and effective for enhancing the immune function of patients with HIV.
- Trial name
- NCT00051818
- Testing
- Treatment interruption/reinitiation schedule
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Wistar Institute
Critical Illness
Impact of Supplemental Parenteral Nutrition in ICU Patients on Metabolic, Inflammatory and Immune Responses
Having previously demonstrated that supplemental parenteral nutrition to complete an insufficient enteral nutrition (EN) between D4 and D8 improves outcome after critical illness, by reducing infectious complications, the present…
- Trial name
- SPN2 (NCT02022813)
- Testing
- Supplemental parenteral nutrition (SPN)
- Where
- 2 sites in Switzerland
- Volunteers
- 28 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Exercise Training
Effect of Aronia Supplementation on the LPS-CD14-TLR2/4 Axis in Football Players
This randomized, double-blind, placebo-controlled trial will investigate the effects of 8-week Aronia melanocarpa supplementation on exercise-induced activation of the LPS-LBP-CD14-TLR2/TLR4 axis in trained male football players.
- Trial name
- ARONIA-TLR (NCT07829523)
- Testing
- Aronia melanocarpa Extract
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hanna Dziewiecka
Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID)
Evaluation of Patients With Immune Function Abnormalities
This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation.
- Conditions
- Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID), Leukocyte Adhesion Deficiency 1 (LAD), Graft Versus Host Disease (cGvHD)
- Trial name
- NCT00128973
- Where
- United States
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever With Warning Signs
Phase 3b Trial To Evaluate Safety And Immune Response (Superiority) of a Two-Dose Butantan-DV Regimen And The Standard Single Dose In Dengue-Naive Children/Adolescents and Immune Response (Non-inferiority) in a Manufacturing Facility Change (DEN-06-IB)
This randomized, double-blind, three parallel-group, multicenter, phase 3b trial evaluates the safety and immunogenicity of Butantan-DV. The study compares two primary immunization regimens (Butantan-DV/Butantan-DV vs.
- Trial name
- DEN-06-IB (NCT07712926)
- Testing
- Butantan-DV (IB), Butantan-DV (WuXi)
- Volunteers
- 1,765 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Toxoplasmosis, Toxoplasma Infections
Diagnosis of Toxoplasma Gondii Infection by Exploration of Cellular Immunity (TOXCELL)
Toxoplasmosis is a parasitic disease caused by Toxoplasma gondii and transmitted to humans through the consumption of raw or undercooked infected meat and / or by poorly washed vegetables.
- Conditions
- Toxoplasmosis, Toxoplasma Infections, Toxoplasmosis, Congenital, Toxoplasmosis Recurrent
- Trial name
- TOXCELL (NCT04825600)
- Testing
- anti-Toxoplasma gondii IgG and IgM dosage, cellular test
- Where
- France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Healthy
Observational Study of Immune Response to Hepatitis B Childhood Booster
The UK immunisation guidelines recommend that children immunised with an accelerated course of hepatitis B vaccine (i.e. vaccination at 0, 1, 2 and 12 months) receive an additional booster dose of vaccine in later childhood…
- Trial name
- NCT00873652
- Testing
- Engerix B®, a recombinant hepatitis B vaccine
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
HSCT from an allogeneic donor is the standard therapy for high-risk hematopoietic malignancies and a wide range of severe non-malignant diseases of the blood and immune system.
- Conditions
- Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, in Relapse, High Risk Acute Lymphoblastic Leukemia
- Trial name
- NCT05066958
- Testing
- boost anti-viral immunity after T-cell depleted HSCT
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Liver Metastasis Colon Cancer
Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer
The goal of this pilot clinical trial is to learn about the combination of immune boosting drugs and irreversible electroporation (IRE) in patients with colon cancer that has spread to the liver (metastasis).
- Trial name
- NCT06047015
- Testing
- IRE plus checkpoint inhibitor, IRE plus Checkpoint Inhibitor plus CpG-ODN
- Volunteers
- 12 people
- Sponsor
- University of Saskatchewan